Prevalence of the metabolic syndrome in schizophrenic patients receiving second-generation antipsychotic agents-A cross-sectional study

Journal of Pharmacy Practice

Volumn 25, Issue 3, 2012, Pages 368-373

  Kagal, Urmila A ^a   Torgal, Shashikant S ^a   Patil, Nanasaheb M ^a   Malleshappa, Anil ^a  

^a JAWAHARLAL NEHRU MEDICAL COLLEGE   (India)

Author keywords

metabolic syndrome; olanzapine; quetiapine; risperidone; schizophrenia

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL;

ADULT; AGED; AMERICAN HEART ASSOCIATION AND NATIONAL HEART LUNG AND BLOOD INSTITUTE; ARTICLE; BLOOD PRESSURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NATIONAL CHOLESTEROL EDUCATION PROGRAM ADULT TREATMENT PANEL III; PREVALENCE; SCHIZOPHRENIA; SCREENING TEST; SENSITIVITY AND SPECIFICITY; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84866279981     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190012442220     Document Type: Article

References (19)

1. Laurie SM, Johnstone EC Companion to Psychiatric Studies. 7 th ed. London, UK: Churchill Livingstone; 2004: 390-420. Johnstone EC Cunningham Owens DG Laurie SM Sharpe E Freeman CPL, ed. London, UK: Churchill Livingstone ; 2004: 390-420.
2. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004 ; 27 (2). 596-601
3. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Eng J Med. 2005 ; 353 (12). 1209-1223 (Pubitemid 41345943)
4. Sahoo S, Manjunatha N, Ameen S, et al. Metabolic syndrome in first episode schizophrenia-a randomized double-blind, controlled short-term prospective study. Schizophr Res. 2008 ; 101 (1-3). 266-272
5. De Hert M, Schreurs V, Vancampfort D, et al. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009 ; 8 (1). 15-22
6. De Hert M, VanWinkel R, Van Eyck D, et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Ment Health. 2006 ; 2: 14
7. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome-an American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation. 2005 ; 112 (17). 2735-2752 (Pubitemid 41532612)
8. Rifai N, Warnick GR, Remaley AT Teitz Fundamentals of Clinical Chemistry. 6 th ed. St Louis, MO: Saunders; 2008: 402-430. Burtis CA Ashwood ER Burns DE, ed. St Louis, MO: Saunders ; 2008: 402-430.
9. Sacks DB Teitz Fundamentals of Clinical Chemistry. 6 th ed. St Louis. MO: Saunders; 2008:373-401. Burtis CA Ashwood ER Burns DE, ed. St Louis. MO: Saunders ; 2008: 373-401.
10. Lalkhen AG, McCluskey A. Clinical tests: sensitivity and specificity. Contin Educ Anaesth, Crit Care Pain. 2008 ; 6: 221-223
11. Park K. Park's Textbook of Preventive and Social Medicine. 19 th ed. Jabalpur, India: M/s Banarsidas Bhanot; 2007: 115-122. Park K,, ed. Jabalpur, India: M/s Banarsidas Bhanot ; 2007: 115-122.
12. McLaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003 ; 139 (10). 802-809
13. Heiskanen T, Niskanen L, Lytikanen R, et al. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry. 2003 ; 64 (5). 575-579 (Pubitemid 36618288)
14. Almeras N, Despres JP, Villeneuve J, et al. Development of an atherogenic metabolic risk profile associated with use of atypical antipsychotics. J Clin Psychiatry. 2004 ; 65 (4). 557-564
15. Meyer J, Loh C, Leckband SG, et al. Prevalence of the metabolic syndrome in veterans with schizophrenia. J Psychiatr Pract. 2006 ; 12 (1). 5-10 (Pubitemid 44378042)
16. Deepa M, Farooq S, Datta M, et al. Prevalence of metabolic syndrome using WHO, ATP III and IDF definitions in Asian Indians: The Chennai Urban Rural Epidemiology Study (CURES-34). Diabetes Metab Res Rev. 2007 ; 23 (2). 127-134
17. Smith M, Hopkins D, Peveler RC, et al. First vs second generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2008 ; 192 (6). 406-411 (Pubitemid 351809892)
18. Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs. 2004 ; 64 (7). 701-723 (Pubitemid 38471372)
19. Kelly DL, Boggs DL, Conley RR. Reaching for wellness in schizophrenia. Psychiatr Clin North Am. 2007 ; 30 (3). 453-479 (Pubitemid 47284562)